The primary questions that this clinical trial aims to answer are:
To compare the differences in the efficacy of different doses of Computerized Cognitive Training (CCT) in improving cognitive function among patients with Mild Cognitive Impairment (MCI), and to explore the potential optimal intervention dose.
To analyze the interaction between individual characteristics and the intervention dose of CCT.
To compare the improvement in functional activity ability of MCI patients among different CCT intervention dose groups.
To compare the symptoms of depression and anxiety among different CCT intervention dose groups.
To evaluate the adherence to different doses of CCT intervention.
Participants will:
Receive CCT intervention at varying durations and frequencies over a 12-week period, and will be followed up for cognitive function, functional activity ability, etc., at weeks 4, 12, and 24.
Age ≥ 60 years.
Self-reported cognitive decline, confirmed by an informant.
Montreal Cognitive Assessment (MoCA) score of 19-25, adjusted for years of education (+1 point for 12 years or less).
Ability to complete activities of daily living independently.
Presence of underlying neurological diseases that may impair cognitive function, including but not limited to dementia syndrome, Parkinson's disease, epilepsy, and cerebrovascular disease.
Presence of severe or unstable organic diseases such as cancer, hydrocephalus, history of central nervous system tumors, or acute brain injury/infection.
Diagnosis of severe mental illness such as major depressive disorder, schizophrenia, schizoaffective disorder, or bipolar disorder.
Presence of severe visual or hearing impairment, or other physical conditions that may interfere with the completion of the study.
6
Treatment groupsSee each treatment group below.